1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends

RHB-103 (Migraine) - Forecast and Market Analysis to 2023

  • March 2014
  • 54 pages
  • GlobalData
Report ID: 2114403

Summary

Table of Contents

RHB-103 (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

RedHill Biopharma (RedHill) is co-developing rizatriptan film (RHB-103) with IntelGenx, using the latter’s VersaFilm propriety thin film technology. Rizatriptan belongs to the triptan class of drugs which target the 5-HT1B and 5-HT1D receptor subtypes. These are located on the extracerebral, intracranial blood vessels, which dilate during the migraine attack, and also located on the nerve terminals of the trigeminal system. Inhibition of these receptors constricts cranial vessels, blocks neuropeptide release and reduces neurotransmission in the trigeminal pain pathways.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on RHB-103 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for RHB-103 for the top six countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of RHB-103 performance
- Obtain sales forecast for RHB-103 from 2012-2023 in the top six countries (the US, France, Germany, Italy, Spain and the UK.).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Migraine Disease Coverage Forecast and Market Analysis

  • $ 22000
  • Industry report
  • July 2017
  • by Datamonitor Healthcare

Introduction Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range ...

Pain Medication OTC Manufacturing in Australia - Industry Market Research Report

  • $ 905
  • Industry report
  • March 2017
  • by Ibisworld

Even dose: Revenue steady over the past five years due to downward price pressure Abstract Pain Medication OTC Manufacturing in Australia Industry companies research and develop over-the-counter (OTC) ...

Global Migraine Market: Industry Analysis & Outlook (2017-2021)

  • $ 800
  • Industry report
  • June 2017
  • by Koncept Analytics

Migraine is a chronic neurovascular disorder characterized by severe recurrent headaches. It is one of the most common and most prevalent disabling neurological conditions, characterized by episodes often ...

Migraine Kol Interview

April 2017 $ 599

Analgesics In Singapore

December 2016 $ 912

Download Unlimited Documents from Trusted Public Sources

Gastrointestinal Drug Markets in the US

  • July 2017
    8 pages
  • Gastrointestina...  

  • United States  

View report >

Pain Relief Statistics in the US

  • July 2017
    21 pages
  • Pain Relief  

  • United States  

View report >

Pain Relief Industry in the US

  • July 2017
    9 pages
  • Pain Relief  

  • United States  

View report >

Analgesic Market

26 days ago

Related Market Segments :

Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.